Identification of a Serotonin 2A Receptor Subtype of Schizophrenia Spectrum Disorders With Pimavanserin: The Sub-Sero Proof-of-principle Study
Latest Information Update: 11 Dec 2024
At a glance
- Drugs Pimavanserin (Primary)
- Indications Schizophrenia and disorders with psychotic features
- Focus Therapeutic Use
Most Recent Events
- 28 Apr 2021 Status changed from not yet recruiting to withdrawn prior to enrolment since drug supply withdrawn.
- 25 Jun 2019 New trial record